[Click eStock] "BioPlus, 2Q HA Filler Sales Show High Growth"

[Asia Economy Reporter Ji Yeon-jin] Cape Investment & Securities announced on the 31st that it expects BioPlus's main business, hyaluronic acid (HA) filler sales, to exceed 9 billion KRW in the second quarter of this year, driving the company's overall sales, and recommended a buy rating with a target price of 38,000 KRW. The target price was calculated by applying a price-to-earnings ratio (PER) of 25 times to the expected earnings per share (EPS) for this year.

BioPlus is expected to record sales of 13.7 billion KRW in the second quarter, a 45.6% increase compared to the same period last year, and an operating profit of 6.6 billion KRW, up 29.2%.

Researcher An Joo-won of Cape Investment & Securities said, "The HA filler sales, the main business, are expected to exceed 9 billion KRW, leading the company's overall growth," adding, "Currently, steady and balanced sales are observed across countries including Europe, Asia, and domestically, maintaining not only sales expansion but also high profitability. The operating profit margin for the second quarter is also estimated to improve by 1.5 percentage points from the previous quarter to 48%."

The expected performance for this year is sales of 56.7 billion KRW, an increase of 51.5%, and operating profit of 27.2 billion KRW, up 49.0%. HA filler sales are projected to grow 27% year-on-year to 38.9 billion KRW, and adhesion prevention agents are expected to reach 5.5 billion KRW.

This content was produced with the assistance of AI translation services.